In contrast, the TME demonstrates anti-tumor activity by engaging cytotoxic T cells or signaling pathways that interact with immune cells (including nuclear factor kappa-light-chain-enhancers of activated B cells (NF-κB)) [15,16,17]. The gene discussed is NFKB1; the disease is neoplasm.